Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

GSK Files Promacta NDA For Short-Term Treatment Of ITP

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

If approved, drug will be first oral platelet growth factor for idiopathic thrombocytopenic purpura.

You may also be interested in...



FDA’s ODAC Concerned About Off-Label, Long-Term Promacta Use

GlaxoSmithKline’s ITP treatment gets panel review May 30 onsite at ASCO.

FDA’s ODAC Concerned About Off-Label, Long-Term Promacta Use

GlaxoSmithKline’s ITP treatment gets panel review May 30 onsite at ASCO.

Promacta, Doribax Applications Get Advisory Committee Reviews

Amgen’s Enbrel will also be reviewed for a pediatric psoriasis indication.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

German HTA Queries Polivy Benefits Amid Lack Of Evidence

See All
UsernamePublicRestriction

Register

PS065549

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By